<DOC>
	<DOC>NCT02246686</DOC>
	<brief_summary>The study will investigate efficacy of STW5-II as add-on therapy on the rate to remission in patients with mild to moderate ulcerative colitis in an acute flare.</brief_summary>
	<brief_title>Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<criteria>Patients with mild to moderate active ulcerative colitis (UC), i.e. Clinical Activity Index (CAI) â‰¥ 5 up to 10 points (including) Patients in whom the active UC is treated independent from any participation in the current study with oral mesalazine at least 14 days up to maximal 28 days before Visit 2 Age between 18 to 80 years (including) UC may reach from leftsided colitis to pancolitis Severe forms of UC (CAI &gt; 10) Crohn's disease, infectious colitis or undetermined colitis Steroid dependence and steroid resistance Concomitant medication with oral steroids, oral or topic budesonide, biologicals, immune modifiers, immunosuppressants Antibiotics at screening visit, during the course of the study a shortterm use in noncolitic afflictions is allowed, and is documented Prior medication with biologicals, immune modifiers and immunosuppressants &lt; 3 month washout Total colectomy Known allergies to components of STW5II Severe allergic diathesis Topical mesalazine application Known intolerance to azo dyes E110 and E151</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Iberogast N</keyword>
	<keyword>Mild to moderate ulcerative colitis</keyword>
	<keyword>add-on therapy</keyword>
	<keyword>efficacy</keyword>
</DOC>